No Data
No Data
UroGen Pharma Ltd. (NASDAQ:URGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$43.88
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40
Express News | UroGen Submits Completed UGN-102 NDA Seeking Approval
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $60
Express News | HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $60 Price Target
UroGen Pharma Analyst Ratings
No Data